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Abstract
Background: Multiple endocrine neoplasia type 1 (MEN1) syndrome is an autosomal dominant hereditary disorder
characterized by the presence of endocrine tumors affecting the parathyroid, pancreas, and pituitary. A heterozygous
germline inactivating mutation in the MEN1 gene (first hit) may be followed by somatic loss of the remaining normal
copy or somatic mutations in the MEN1 gene (second hit). Whole-exome sequencing has been successfully used to
elucidate the mutations associated with the different types of tumors.
Case presentation: We performed whole-exome sequencing (WES) on three parathyroid tumors, one pancreatic
insulinoma, and a blood sample taken from the same patient with MEN1 to study tumor heterogeneity in MEN1
originating from different tumors. We identified a novel frame-shift deletion (c.1382_1383delAG, p.E461GfsX69) in the
MEN1 gene using WES, which was confirmed by Sanger sequencing. WES and the SNP array revealed somatic LOH on
chromosome 11 in parathyroid tumors (left upper, left lower, and right upper parathyroid). However, we did not detect
a somatic MEN1 gene mutation or LOH in the pancreatic insulinoma. WES revealed two somatic functional variants
outside the MEN1 gene in the pancreatic insulinoma.
Conclusions: This study revealed heterogeneity among tumors in the same patient with MEN1, suggesting that
different tumor-specific tumorigenic mechanisms may contribute to the pathogenesis of MEN1 tumors. The present
study supports the clinical applicability of the WES strategy to research on multiple tumor samples and blood.
Keywords: Multiple endocrine neoplasia type 1, Genetic analysis, Somatic mutation, Whole-exome sequencing, Clinical
genomics, Case report
Background
Multiple endocrine neoplasia type 1 (MEN1) is an auto-
somal dominant inherited tumor syndrome character-
ized by the combined tumors of the parathyroid glands,
pancreas, and pituitary gland [1]. Parathyroid tumors are
the most common clinical manifestation, and the
prevalence of hyperparathyroidism is >90% in patients
with MEN1, whereas those of pancreatic and pituitary
tumors are 40–70% and 30–60%, respectively [2]. MEN1
is caused by germline mutations in the MEN1 tumor
suppressor gene linked to chromosomal locus 11q13 [3].
A heterozygous germline-inactivating mutation of the
MEN1 gene (first hit) may be followed by loss of the
normal copy of this gene or a somatic inactivating muta-
tion (second hit), leading to complete loss of function of
the encoded protein menin [4, 5]. A MEN1 gene muta-
tion analysis has helped identify the cause of various
sporadically occurring tumors of the same type that are
observed in patients with MEN1 syndrome.
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Identifying the genetic cause of the disease has become
useful for diagnosing at-risk carriers affected by MEN1,
and whole-exome sequencing (WES) approaches could
help identify the causative genes [6]. Such an approach
has been successfully used to elucidate mutations associ-
ated with multiple tumor types. Since next-generation
sequencing (NGS) technology was introduced in 2008
[7], comprehensive genomic analyses have accelerated.
With the power to detect novel variants from only a
small number of individuals, NGS is proving invaluable
for modern geneticists, boasting putative diagnostic rates
of 21–25% for rare diseases of unknown etiology [8, 9].
Therefore, we pursued a WES analysis of parathyroid
adenomas and a pancreatic insulinoma to study the
tumor heterogeneity that may be contributing to differ-
ent mechanisms of tumor-specific tumorigenesis.
Case presentation
The proband patient was admitted to hospital with a
chief complaint of flank pain. The patient had been
sweating for 5 years, and was nervous when fasting. The
patient had had multiple episodes of kidney stones
during the past 2 years. Table 1 presents the patient’s
clinical information. The serum calcium level was
13.7 mg/dL (reference range, 8.2–10.8 mg/dL), and
serum intact PTH was 209 pg/mL (reference range,
6–8 pg/mL), indicating primary hyperparathyroidism.
The fasting serum glucose was 48 mg/dL (reference
range, 70–110 mg/dL), and fasting serum insulin was
21.9 μU/mL, with a serum C-peptide level of 3.00 ng/mL
(reference range, 1.06–3.53 ng/mL), indicating endogen-
ous hyperinsulinemia. The anterior pituitary hormones
were within the normal ranges. Sestamibi parathyroid,
neck computed tomography (CT), and neck ultrasonog-
raphy revealed multiple parathyroid adenomas. Abdom-
inal CT revealed an approximately 1.6-cm well-defined
enhancing mass at the head of the pancreas, suggesting an
endocrine tumor. Brain sellar magnetic resonance imaging
showed a normal pituitary. A subtotal parathyroidectomy
and pancreaticoduodenectomy were performed. Postoper-
atively, all hormones and serum calcium returned to their
normal ranges (Fig. 1).
Whole-exome sequencing and validation with Sanger
sequencing
Genomic DNA was isolated from matched tumor tissues
and a constitutional blood sample using standard proto-
cols included in the commercially available QIAGEN
DNeasy Blood and Tissue kit (QIAGEN, Hilden,
Germany). All specimens were quality control checked
for purity using a NanoDrop spectrophotometer and
Qubit Fluorometer (Thermo Fisher Scientific Inc.,
Waltham, MA, USA). Tumor and blood DNA were cap-
tured on the Agilent SureSelect DNA library construc-
tion (SureSelect V4 + UTR; Agilent Technologies, Palo
Alto, CA, USA) and were sequenced on the Illumina
Hiseq2000 instrument (Illumina, Inc., San Diego, CA,
USA), as described by the manufacturer’s protocols for
paired 101-bp reads. Image analysis and base calling was
performed using Illumina pipeline ver. 2.3 with default
parameters.
Reads were aligned to the human reference hg19 genome
assembly using the Burrows–Wheeler Aligner (BWA;
http://bio-bwa.sourceforge.net/), and duplicated read pairs
were removed [10]. Genotypes for single nucleotide vari-
ants (SNVs) and short indels were called using the Genome
Analysis Toolkit (GATK) [11] and Sequence Alignment
Map tool (SAMtools, http://samtools.sourceforge.net/), re-
spectively. Variants were annotated using ANNOVAR
(http://www.openbioinformatics.org/annovar/). Allele fre-
quencies for each variant were estimated based on phase 1
genotypes from the 1000 Genomics Project, the Korean
control exome dataset, which includes the Korean
Reference Genome (KRG database, n = 622). The effects
of the identified variants were assessed using the Sorting
Intolerant Form Tolerant (SIFT, http://sift.jcvi.org), and
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2), auto-
matic tools for predicting the possible impact of an amino
acid substitution on the structure and function of a hu-
man protein [12, 13].
Sanger sequencing was used as an alternate plat-
form to validate the identified variants in the four
exome-sequenced tumor samples. Primer3 (http://
frodo.wi.mit.edu/primer3/) was used to generate
primers to amplify variants identified via exome se-
quencing. Amplicons from blood and tumor genomic
DNA were analyzed using gel electrophoresis and
were sequenced using an ABI 3730 genetic analyzer
(Applied Biosystems, Foster City, CA) with forward
and reverse primers.




Primary hyperparathyroidism (Parathyroid adenoma)
Calcium 13.7 ▲ mg/dL 8.2–10.8
Phosphorus 2.3 ▼ mg/dL 2.5–5.5
PTH-intact 209 ▲ pg/mL 8–6
PTH related peptide (PTHrP) 1.1 <1.1
Creatinine 2.00 ▲ mg/dL 0.60–0.20
Insulinoma (enteropancreatic tumor)
C-peptide (serum) 3.00 ng/mL 1.06–3.53
Glucose 48 ▼ mg/dL 70–110
Insulin 21.9 ▲ μIU/mL
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Genotyping and identification of loss of heterozygosity
Samples were genotyped with the Illumina Human
Omni2.5–8 BeadChip according to the manufacturer’s
protocols, and the genotypes were called using Geno-
meStudio software (Illumina) with standard cluster defi-
nitions. GenomeStudio provides raw data normalization,
clustering, and genotype calling and calculates a GenCall
score for each genotype, which is a measure of the accur-
acy of the genotype call. A 1-Mb sliding window across
each chromosome was used to determine large regions
with LOH in the tumor samples. The SNP array extracted
both the log2 intensity ratio (LogR) and the B allele fre-
quency (BAF) data. LogR measures the intensity of a sam-
ple relative to the reference intensity, and BAF measures
the allele frequency at a particular SNP along the genome.
Whole-exome sequence analysis
We performed WES on three parathyroid and one pan-
creatic tumor specimens as well as on a whole blood
sample from the same patient diagnosed with MEN1.
We sequenced the tumor and germline DNA isolated
from whole blood to identify somatic changes in the
tumors.
We provided an analytical pipeline to detect germline
or tumor-specific somatic variations in which each sam-
ple was considered independently. The genomic pipeline
is outlined in Fig. 2a. Raw reads (fastq files) were first
quality checked with FastQC. Filtered reads were aligned
to the appropriate reference genome using BWA, and
duplicate reads were marked using Picard. As the tumor
and blood BAM files were merged to detect the somatic
variants, the SNVs and indel calling were performed
using two separate callers to assist in identifying true-
positive somatic variant calls while reducing the false-
positive calls.
WES metrics and summary statistics for each speci-
men are shown in Fig. 2b. We generated nearly 100 bil-
lion total reads from WES, for an average mapped
coverage of 66–98. To evaluate the overall quality of the
variant data, germline SNVs were called, and the transi-
tion to transversion and 135 dbSNP (Single Nucleotide
Polymorphism Database) concordance ratios were calcu-
lated. We used the GATK and SAMtools programs to
identify somatic SNVs and indels, respectively, and
found a high validation rate for the variants called by
program. The identified variants were combined into
single file and annotated using ANNOVAR to add infor-
mation, such the gene variants, consequence of the mu-
tation (nonsynonymous, nonsense, etc.), and information
from databases (e.g., PolyPhen2, SIFT, dbSNP, OMIN,
and COSMIC). The final output of the pipeline con-
sisted of a single file containing the annotated variants
Fig. 1 Case subject. a Neck computed tomography (CT) scan: Heterogeneous enhancing mass with cystic changes in both paratracheal (right 1.5 cm,
left 2.2 cm) and parathyroid adenomas. b Abdominal CT: About a 1.6-cm well-defined enhancing mass at the head of the pancreas; R/O endocrine
tumor. c Sellar magnetic resonance imaging: Normal pituitary. d Sestamibi parathyroid scan: Multiple parathyroid adenoma. e Endoscopic ultrasound
and fine need aspiration: About a 1.6-cm-sized round hypoechoic homogenous mass at the pancreatic head. Immunohistochemistry: Ki-67 index <1%,
P53: (−), synaptophysin: (+), neuroendocrine tumor. f KUB X-ray: Huge calyceal stones, Rt. kidney. g Pedigree of the patient with multiple endocrine
neoplasia type1 (MEN1). The affected subject is indicated by the arrow. h Novel germline mutation in the MEN1 gene. Sanger sequence of MEN1
codons 462 in a wild-type subject and patient are shown and confirmed the c.1382_1383delAG mutation. Mutated residue is indicated by an asterisk,
and the encoded amino acids are shown as single-letter code
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from the tumor and blood samples. These analyses indi-
cated that no biases were encountered with respect to
nucleotide substitutions. SNPs identified in the data
were strongly correlated with common genetic varia-
tions, indicating that high-quality variant calling was
performed.
Novel germline mutation in the MEN1 gene
The nine exons of the MEN1 gene as well as their flanking
introns were amplified and subjected to Sanger sequen-
cing. Herein, we confirmed four germline variants of the
MEN1 gene by WES and Sanger sequencing, and the dis-
tribution is shown in Table 2. Mutations were found in
exons 9 and 10 (one frameshift deletion, one missense
mutation, and two synonymous variants). A novel germ-
line mutation (c.1382_1383delAG/p.E462GfsX69) was
newly confirmed in the present study, and the other three
have been reported previously in the 1000 Genome
Project and the Korean control exome dataset. This novel
germline mutation (c.1382_1383delAG) was also present
in all four tumor samples according to the WES analysis.
The brother and son of the proband did not harbor this
mutation (Fig. 1h). All variants were confirmed based on
the NCBI SNP database (http://www.cnbi.nlm.nih.gov/
SNP) and the Human Gene Mutation Database (http://
www.hgmd.org).
Detecting loss of heterozygosity
Oligonucleotide-based SNP genotyping array has been
used to measure physical copy number and genetic aber-
rations, such as LOH. We included three additional
MEN1 parathyroid specimens and one pancreatic speci-
men for which there was a paired germline sample
(blood). Three tissue samples (left upper, left lower, and
right upper parathyroid) had chromosomal allelic imbal-
ance events (LOH with chromosomal loss).
Additional file 2: Figure S1 illustrates a greater degree
of chromosomal allelic imbalance across the MEN1
tumor genomes compared with that in the blood sample.
The SNP array collects intensity and allelic information,
allowing two different genomic profiles to be generated.
The log2 intensity ratio measures the intensity of a sam-
ple relative to a reference intensity, and the B allele fre-
quency (BAF) measures the allele frequency at a
particular SNP along the genome. The expected BAF
value at a normal (non-LOH) polymorphic position is
0.5, and a significant deviation from 0.5 identifies LOH.
LOH can easily be observed using the BAF plot by not-
ing an absence of heterozygotes. Of note, there was con-
sistent LOH of chromosome 11 (where the MEN1 gene
resides) across all three of the parathyroid tumor sam-
ples from the patient with MEN1, whereas the pancre-
atic tumor exhibited no chromosomal LOH events
Identifying tumor-specific somatic mutations
WES was performed on tumor and constitutional DNA
samples from the patient with MEN1. The raw sequen-
cing data were mapped to the hg19 reference human
genome, the variants were identified, and tumor and
constitutional blood sequences from each tumor were
cross-referenced to identify somatic variants unique to
each tumor genome.
WES was performed on the three parathyroid and one
pancreatic tumors demonstrated an average of 180 vari-
ants in GATK and 389 in SAMtools. Additional file 1:
Table S1 summarizes the number of somatic variants
observed in the parathyroid and pancreatic tumors.
Total somatic variants were examined using computa-
tional metrics and manual read alignment analysis to
Fig. 2 Whole-exome sequencing analytical pipelines. a Two workflows are present: Germline detection and somatic detection. Red highlights the
difference between our germline pipeline and the somatic pipeline. b Summary exome sequencing statistics for all four tumor tissues and blood
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identify mutations with a high likelihood of being false
positives.
The variants identified were annotated based on nov-
elty, impact on the encoded protein, and conservation.
Across all four tumor types, nine variants were identified
in the coding region; two events were detected in the left
upper parathyroid, three in the left lower parathyroid,
two in the right upper parathyroid, and two in the pan-
creas. Of these events, we identified three indels and six
nonsynonymous SNVs. A summary of the somatic vari-
ants identified in each tumor are shown in Table 3. Nine
somatic variants, which were not present in the
leukocyte samples, and, therefore, were not germline.
Two somatic functional mutations outside the MEN1
gene were identified in the pancreatic insulinoma by
WES. No somatic MEN1 gene mutation was found in
any of the four tumors.
Discussion and conclusions
Genome-wide investigation of tumor and blood samples
using WES and SNP array detected a novel MEN1
germline mutation (first hit) and tumor somatic muta-
tions (second hit), confirming the two-hit model for
tumor-suppressor genes. The heterogeneity between tu-
mors (LOH in parathyroid tumors and no LOH in the
pancreatic tumor) within a single patient suggests poly-
clonal tumorigenesis related to a predisposition arising
from a single germline mutation.
The novel MEN1 germline mutation (c.1382_1383delAG;
p.E462GfsX69) discovered in the present study was discov-
ered by WES and confirmed by Sanger sequencing. This
mutation was found in all four tumor samples and the
blood sample and has not been reported in dbSNP135, the
1000 Genome Project, or the Korean control exome data-
set. The brother and son of the proband did not harbor this
mutation. The present study contributes to medical science
by reporting a novel MEN1 germline mutation causing
MEN1 syndrome and supports the clinical applicability of
using WES to discover a causative mutation in the proband
and to perform genetic testing on family members.
The LOH analysis detected the presence of chromo-
some 11 (where the MEN1 gene resides) LOH with
chromosomal loss in all three parathyroid tumors. These
findings demonstrate that the MEN1 germline mutation
(first hit) and the chromosome 11 LOH (second hit)
caused biallelic inactivation of the tumor suppressor
MEN1 gene, which drives tumorigenesis of these tumors
(Fig. 3). Additional chromosomal abnormalities were de-
tected in the left lower part of the parathyroid tumor,
suggesting the occurrence of possible genome instability
and passenger mutations, as reported previously in simi-
lar studies on parathyroid tumors [14, 15]. No sign of
LOH was found in the pancreatic tumor sample, sug-
gesting that the mechanism of a MEN1 pancreatic
tumor may be different from that of a MEN1 parathy-
roid tumor. These findings suggest that polyclonal
tumorigenesis is related to a predisposition arising from
a single germline mutation in MEN1 syndrome.
The somatic mutation analysis using WES revealed
several possible driver mutations (other than MEN1).
Because the pancreatic tumor did not harbor the MEN1
inactivation mutation (e.g., chromosome 11 LOH in the
parathyroid tumors), we tried to determine the possible
driver mutations involved in tumorigenesis in addition
to the haploinsufficiency of the germline MEN1 muta-
tion. One stop-gain mutation in the ZNF429 gene and
one frameshift mutation in the SCARF2 gene were dis-
covered in the pancreatic tumor sample. These muta-
tions may make a contribution to the tumorigenesis that
is in addition to that made by the predisposition arising
from the germline MEN1 mutation. However, these
somatic mutations from the parathyroid and pancreatic
tumors may simply be passenger mutations resulting
from tumorigenesis. It is difficult to distinguish a driver
mutation from a passenger mutation in tumor samples
using the WES approach.
We discussed a WES base analytical pipeline that
detected germline and somatic variations by performing
variant calling using two algorithms (GATK and
SAMtools) to assist in identifying true-positive variant
calls. To increase the validation rate, SNVs and indels
were filtered with a mapping quality score > 58 in GATK
and SAMtools. According to the SNP quality (SNPQ)
and strand bias (SB) analyses, the variants were filtered
with SNPQ ≥300, SB < −10 in GATK and SNPQ ≥40,
and 20 ≤ AF% < 80 in SAMtools. These parameters are
based on a previous study [16].
Here, we compared the WES platform results, which
use depth of coverage and alternative allele frequencies
from mapped sequenced reads to estimate LOH, with
those of the SNP genotyping array. In the WES analysis,
homozygous alleles were observed in chromosome 11 in
all three parathyroid tumor samples, indicating LOH.
Array Comparative Genomic Hybridization (aCGH) and
SNP genotyping arrays have been widely used as stand-
ard methods to detect copy-number variation and LOH.
However, with the rapid increase in genomic and exomic
sequencing, LOH can be detected by WES, extending
the ability of this powerful approach [17]. The resolution
of these methods is limited by depth of coverage and the
capture probe design. These data suggest that a WES-
based platform is sufficient for identifying the genetic
causes of various diseases in a diagnostic analysis and
can be used to estimate germline and somatic mutations,
as well as LOH simultaneously.
NGS allows characterization of genetic diseases with
high accuracy and low cost. In particular, WES is an alter-
native approach to discovering variants that offers high
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specificity and sensitivity [18] and can be used to identify
causative mutations in a number of Mendelian disorders,
including monogenic diseases, as most causative muta-
tions are on protein-coding regions. It also has the poten-
tial to identify de novo genetic variations through the
WES platform. For these reasons, WES could be a surro-
gate to discover medically relevant genomic variations and
diagnose genetic diseases at a genome-wide scale.
We identified a novel MEN1 germline mutation and
tumor-specific somatic variants in a patient with MEN1
and multiple parathyroid and pancreatic tumors. Hetero-
geneity between tumors within a single patient suggests
polyclonal tumorigenesis related to a predisposition aris-
ing from a single germline mutation. The present study
demonstrates the clinical applicability of the WES
strategy, which uses multiple tumor samples and a blood
sample, to investigations of disease pathogenesis and
evaluations of clinical genetics for patients and family
members.
Additional files
Additional file 1: Table S1. Number of somatic variants observed in
four tumor types. (DOC 64 kb)
Additional file 2: Figure S1. Analysis of loss of heterozygosity (LOH) by
single-nucleotide polymorphism (SNP) arrays. (A) Chromosomal alteration
(gain, loss, or loss of heterozygosity) in parathyroid and pancreatic tumors.
LOH of 11 was detected in the parathyroid tumor. LOH can easily be
observed using a B allele frequency (BAF) plot by noting the absence of
heterozygotes. (B) Chromosome 11 from parathyroid and pancreas. The
upper part of the panel shows genotypes of the SNPs expressed as the BAF.
The lower part of the panel shows the DNA copy number expressed on a
base-2 log scale (log ratio), and the red line corresponds to two copies of
DNA. (TIFF 789 kb)
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